Should I buy or sell Coya Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coya Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COYA shares. View COYA analyst ratings or view top-rated stocks .

What is Coya Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 1 year target prices for Coya Therapeutics' shares. Their COYA share price targets range from $14.00 to $14.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price. View analysts price targets for COYA or view top-rated stocks among Wall Street analysts .

How have COYA shares performed in 2024?

Coya Therapeutics' stock was trading at $7.41 at the start of the year. Since then, COYA shares have increased by 13.0% and is now trading at $8.37. View the best growth stocks for 2024 here .

Are investors shorting Coya Therapeutics?

Coya Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 191,100 shares, an increase of 309.2% from the March 15th total of 46,700 shares. Based on an average daily volume of 94,200 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.5% of the company's shares are short sold. View Coya Therapeutics' Short Interest .

When is Coya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our COYA earnings forecast .

How were Coya Therapeutics' earnings last quarter?

Coya Therapeutics, Inc. (NASDAQ:COYA) posted its quarterly earnings data on Tuesday, March, 19th. The company reported $0.15 earnings per share (EPS) for the quarter. The firm earned $6 million during the quarter.

When did Coya Therapeutics IPO?

Coya Therapeutics (COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share.

How do I buy shares of Coya Therapeutics?

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:COYA

Coya Therapeutics (COYA) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free COYA Stock Alerts

$8.37

-0.65 (-7.21%)

(As of 04/15/2024 ET)

Compare

Today's Range: $8.20
▼
$9.05
50-Day Range: $5.83
▼
$10.13
52-Week Range: $3.21
▼
$10.69

Volume: 75,035 shs
Average Volume: 89,607 shs
Market Capitalization: $122.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Get Coya Therapeutics alerts:

Coya Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 67.3% Upside
$14.00 Price Target
Short Interest: Healthy
1.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.56
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.31 out of 5 stars

Medical Sector

757th out of 929 stocks

Pharmaceutical Preparations Industry

342nd out of 422 stocks

3.5

Analyst's Opinion

Consensus Rating
Coya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Coya Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.53% of the float of Coya Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Coya Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Coya Therapeutics has recently increased by 309.21%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Coya Therapeutics does not currently pay a dividend.
Dividend Growth
Coya Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for COYA.

2.5

News and Social Media Coverage

News Sentiment
Coya Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Coya Therapeutics this week, compared to 2 articles on an average week.
Search Interest
15 people have searched for COYA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coya Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.80% of the stock of Coya Therapeutics is held by insiders.
Percentage Held by Institutions
Only 39.75% of the stock of Coya Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Coya Therapeutics is -10.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Coya Therapeutics is -10.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Coya Therapeutics has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Coya Therapeutics Stock (NASDAQ:COYA)

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

COYA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

COYA Stock News Headlines

April 15, 2024 | finance.yahoo.com

Coya Therapeutics, Inc. (COYA) Interactive Stock Chart - Yahoo Finance

April 12, 2024 | americanbankingnews.com

Head-To-Head Comparison: Coya Therapeutics (COYA) & Its Peers

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 8, 2024 | businesswire.com

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

April 6, 2024 | americanbankingnews.com

Financial Contrast: Coya Therapeutics (COYA) versus Its Competitors

March 27, 2024 | finance.yahoo.com

We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate

March 21, 2024 | finance.yahoo.com

Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates

March 19, 2024 | investorplace.com

COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 19, 2024 | finance.yahoo.com

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

March 14, 2024 | investing.com

Coya presents promising ALS biomarker data at conference

March 13, 2024 | msn.com

New treatment for ALS provides hope for Maine families battling disease

March 12, 2024 | finance.yahoo.com

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

March 12, 2024 | finance.yahoo.com

Coya Therapeutics to Participate in BTIG Fireside Discussion

March 10, 2024 | markets.businessinsider.com

Buy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment Approach

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel Optimism

February 29, 2024 | finance.yahoo.com

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

February 22, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)

February 22, 2024 | msn.com

Coya Inches up Ahead of ALS Address

February 22, 2024 | businesswire.com

Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference

February 21, 2024 | finance.yahoo.com

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"

February 21, 2024 | businesswire.com

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a “Pipeline in a Product”

February 13, 2024 | finance.yahoo.com

Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases

February 5, 2024 | benzinga.com

Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases

February 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Coya Therapeutics Amid Promising Drug Development and Regulatory Milestones

January 29, 2024 | finance.yahoo.com

Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference

January 18, 2024 | finance.yahoo.com

Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series

See More Headlines

Receive COYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:COYA
CUSIP: N/A
CIK: 1835022
Web: www.coyatherapeutics.com
Phone: 800-587-8170
Fax: N/A
Employees: 8
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $14.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +67.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,990,000.00
Net Margins: N/A
Pretax Margin: -121.03%
Return on Equity: -42.53%
Return on Assets: -37.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.15
Quick Ratio: 8.15

Sales & Book Value

Annual Sales: $6 million
Price / Sales: 20.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.47 per share
Price / Book: 3.39

Miscellaneous

Outstanding Shares: 14,600,000
Free Float: 13,171,000
Market Cap: $122.20 million
Optionable: Not Optionable
Beta: 0.80

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Howard Berman Ph.D. (Age 50)
Chairman & CEO
Comp: $598.12k
Mr. David S. Snyder (Age 64)
CFO & COO
Comp: $465.27k
Dr. Fred Grossman D.O.
FAPA, President & Chief Medical Officer
Dr. Gregory MacMichael Ph.D. (Age 68)
Chief Technical Officer
Dr. Michelle Frazier Ph.D.
Senior Vice President of Regulatory Affairs
Mr. Aaron Thome Ph.D.
Head of Neuroinflammation Platform
Dr. Arun Swaminathan Ph.D.
Chief Business Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

COYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Coya Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coya Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COYA shares.
View COYA analyst ratings or view top-rated stocks.
What is Coya Therapeutics' stock price target for 2024?: 2 Wall Street research analysts have issued 1 year target prices for Coya Therapeutics' shares. Their COYA share price targets range from $14.00 to $14.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price.
View analysts price targets for COYA or view top-rated stocks among Wall Street analysts.
How have COYA shares performed in 2024?: Coya Therapeutics' stock was trading at $7.41 at the start of the year. Since then, COYA shares have increased by 13.0% and is now trading at $8.37.
View the best growth stocks for 2024 here.
Are investors shorting Coya Therapeutics?: Coya Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 191,100 shares, an increase of 309.2% from the March 15th total of 46,700 shares. Based on an average daily volume of 94,200 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.5% of the company's shares are short sold.
View Coya Therapeutics' Short Interest.

When is Coya Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our COYA earnings forecast.
How were Coya Therapeutics' earnings last quarter?: Coya Therapeutics, Inc. (NASDAQ:COYA) posted its quarterly earnings data on Tuesday, March, 19th. The company reported $0.15 earnings per share (EPS) for the quarter. The firm earned $6 million during the quarter.
When did Coya Therapeutics IPO?: Coya Therapeutics (COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share.
How do I buy shares of Coya Therapeutics?: Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COYA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Coya Therapeutics (COYA) Stock Price, News & Analysis

Coya Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Coya Therapeutics Stock (NASDAQ:COYA)

COYA Stock Price History

COYA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

COYA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™